Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT05446870
Title Pembrolizumab With Chemotherapy and MK-4830 for Treating Participants With Ovarian Cancer (MK-4830-002)
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors Merck Sharp & Dohme LLC
Age Groups: senior | adult
Covered Countries USA | ITA | ESP | CAN | BEL

No variant requirements are available.